Good MorningU.S. stocks delivered a mixed session Tuesday, with the Nasdaq closing at a fresh record, the S&P 500 finishing roughly flat and the Dow retreating as oil prices declined. Brent crude fell below $100 per barrel during the session as investors weighed potential improvements in Middle East oil flows alongside continued geopolitical risks. President Trump also threatened further action against Iran if a deal to end the conflict is not reached.
Technology remained central to trading. Bank stocks, including JPMorgan Chase, Bank of America and Citigroup, fell as investors focused on narrowing Treasury yield spreads and the potential pressure on lending margins. Qualcomm introduced two new flagship Snapdragon smartphone processors designed around on-device and agentic AI capabilities. Apple shares reached a new intraday record and briefly pushed the company's market capitalization above $5 trillion, while Microsoft opened a Maryland quantum research center that will give DARPA direct access to its latest quantum-computing hardware.
Corporate activity remained active. Progress Software completed its $400 million acquisition of substantially all of Domo's AI and data-platform assets, while Sun Communities completed the sale of its U.K. Park Holidays business to Aermont Capital. Willdan also agreed to acquire Mantis Innovation for $285 million in cash, subject to regulatory approval. Featured: Democrats now hold both chambers. Where does that leave savers? (Ad) 
|
Technology | |
When technology stocks move on heavy trading volume, investors look for the structural business evolution beneath the headline. Shares of Arm Holdings PLC (NASDAQ: ARM) recently rose by around 17%, closing near $322.90 as daily volume approached 13 million shares. While conventional wisdom often ca... Read the Full Story |
|
From Our Partners | | A Democratic Congress, a Republican President and a mountain of federal debt that didn't disappear on Election Day. Another debt ceiling standoff could be just around the corner.
Reagan Gold Group's free guide explains why physical gold is back in the retirement conversation and what it means for savings left on autopilot.
Reagan Gold Group is not a financial or tax advisor and has no fiduciary obligations to its clients. | | Request your free guide from Reagan Gold Group to see why gold is back. |
|
Healthcare | |
Oura Inc. (NASDAQ: OURA) launched its roadshow on Sept. 21, 2026, targeting a Nasdaq debut under the ticker OURA during the week of Sept. 28. Offering 50 million shares priced between $40 and $44 each, Oura is targeting an initial market capitalization of around $12.8 billion to $14.1 billion, repr... Read the Full Story |
|
Technology | |
When a chipmaker eclipses a $1 trillion valuation, investors naturally question whether the underlying rally can sustain a durable threat to incumbent leaders. Crossing this historic capitalization threshold places the business alongside elite hardware designers. For institutional capital analyzing... Read the Full Story |
|
From Our Partners | | Money already in an eligible 401(k) or IRA may be used to purchase physical gold through a self-directed gold IRA, which means you may not need to add new funds.
With Washington shifting and uncertainty around inflation and the dollar, more Americans are exploring this option.
Gold isn't immune to losses, and gold IRAs come with fees, rules and risks. Reagan Gold Group is not a financial or tax advisor and has no fiduciary obligations to its clients. | | Request your free guide to self-directed gold IRAs and learn the fees, rules and risks. |
|
Markets | |
The Fed’s latest rate hike looks straightforward on the surface: inflation remains a problem, so policymakers are keeping pressure on the economy. There is reason to believe the FOMC remains behind the curve, as it has been since inflation reared its ugly head. But a case can be made that the commi... Read the Full Story |
|
Technology | |
IonQ Inc. (NYSE: IONQ) has already had an impressive run in 2026, despite shares being down by about 11% year to date (YTD).
Even as the broader quantum computing industry remains highly speculative, IonQ has built up an advantage: it has achieved major sales growth and revenue that lend some supp... Read the Full Story |
|
From Our Partners | | Jon Najarian has identified a tiny company trading under 25 dollars that Elon Musk has already secured rights to acquire up to 15 percent of.
Najarian says the setup mirrors Musk's past moves with Maxwell Technologies, SolarCity, and Swarm - and this target is roughly 2,500 times smaller than SpaceX. | | Watch Jon Najarian's full breakdown before the December 8 deadline |
|
Technology | |
Concerns around security and how artificial intelligence capabilities could evolve have put a spotlight on the pace of frontier model development. After doing so several months ago, Anthropic has again called for measures that would limit how quickly frontier models can improve.
This has understan... Read the Full Story |
|
Technology | |
Microsoft Corp. (NASDAQ: MSFT) has outperformed the S&P 500 and the Nasdaq in 2026. MSFT is up 31% since the end of June as it begins to convince investors that it’s successfully monetizing artificial intelligence.
And recently, the company gave investors yet another reason to own its stock.
... Read the Full Story |
|
Communication Services | |
When state regulators intervened in July 2026 to block Paramount Skydance's acquisition of Warner Bros. Discovery, investors expected a long courtroom fight. Instead, a multi-state antitrust settlement announced on Sept. 21 removed the main legal barrier confronting the approximately $111 billion t... Read the Full Story |
|
Technology | |
For most of the past two years, NVIDIA Corporation (NASDAQ: NVDA) has stood at the summit of the stock market. As the chipmaker whose processors power much of the artificial intelligence boom, it was perhaps no surprise that it became the first company ever to reach a $5 trillion market cap. After ... Read the Full Story |
|
Communication Services | |
When artificial intelligence (AI) models scale from billions to trillions of parameters, the focus often goes to the power and size of the silicon-based processing chips and graphics processing units. However, silicon faces a quiet, physical barrier: data transfer speed.
Modern distributed training... Read the Full Story |
|
Wednesday's Early Bird Stock Of The Day AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. | Should I Buy AbbVie Stock? ABBV Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of AbbVie was last updated on Wednesday, November 04, 2026 at 6:25 PM.
AbbVie Bull Case -
AbbVie recently secured global rights to Nxera Pharma's experimental oral IBD candidate, NXE0033744, in a deal worth up to $1.47 billion including upfront payments and milestones, which diversifies the company's growth pipeline beyond its current immunology and oncology franchises.
-
The company is investing more than £120 million to expand its Oxford R&D facility, signaling a long-term commitment to advancing research in immunology, neurology, and oncology, which supports future product innovation and market expansion.
-
AbbVie reported strong third-quarter earnings with EPS of $3.82, beating analyst estimates of $3.73, and revenue of $17.40 billion, which was also above the consensus of $17.32 billion, demonstrating robust operational performance and demand for its key products like Skyrizi and Rinvoq.
-
Wall Street sentiment has improved significantly, with multiple brokerages including Morgan Stanley and Piper Sandler raising their price targets, and the stock currently trading at $294.15, which is near its 52-week high of $298.74, reflecting strong investor confidence in the company's trajectory.
-
AbbVie recently increased its quarterly dividend to $1.82 per share, representing a 5.2% increase from the previous $1.73, which provides a growing income stream for investors and signals management's confidence in the company's cash flow generation.
AbbVie Bear Case -
AbbVie discontinued a Phase 2 solid-tumor drug program due to "limited benefit," which is a setback for its oncology pipeline and may raise concerns about the success rate of its other experimental cancer treatments.
-
The company's valuation may be stretched after its recent rally, with a P/E ratio of 50.63, which is high compared to many peers, potentially limiting further upside if growth expectations are not met in the coming quarters.
-
AbbVie's payout ratio is currently 119.10%, meaning the company is paying out more in dividends than it is earning in net income, which could be a concern for long-term sustainability of the dividend if earnings do not grow sufficiently.
-
Insider selling has been notable, with EVP Nicholas Donoghoe selling 32,710 shares in August 2026, representing a 30.53% decrease in his position, which some investors may interpret as a lack of confidence in the stock's near-term performance.
-
Short interest has been relatively high, with 15.58 million shares shorted as of October 2026, which is a significant portion of the float and could indicate that some investors are betting against the stock's future performance.
| | View Today's Stock Pick |
|
